126
|
Song GY, Li G, Lu WH, Han B, Xu TM. Distortion and magnification of four digital cephalometric units. Niger J Clin Pract 2019; 22:1644-1653. [PMID: 31793469 DOI: 10.4103/njcp.njcp_184_19] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Objectives To assess the validity of using the calibration ruler for correcting magnification of linear measurements and to explore and compare the vertical and horizontal magnification of four digital cephalometric units. Methods An acrylic box was imaged at seven sagittal positions using four digital cephalometric units: Orthopantomograph OC100, Orthopantomograph OC200, Sirona Orthophos CD, and Sirona Orthophos DS. The true linear lengths of the phantom, corrected, and uncorrected linear lengths on the images were measured and compared. The validity of measurements using the calibration ruler was assessed. The magnification values and distortion indices were calculated and compared among the four cephalometric units. Results For linear measurements on the mid-sagittal plane and averaged linear measurements on bilateral symmetric sagittal planes, the bias 1.96 STD of the calibration ruler ranged from 1% to 2% for the four cephalometric testing units. For linear measurements on the single lateral sagittal plane, the bias 1.96 STD ranged from 3% to 6%. The vertical scanning charge-coupled device cephalometric unit produced the greatest distortion, ranging from 1.029 to 0.964. Conclusion The metal millimeter calibration ruler is an accurate reference for linear measurement magnification correction. Because of unpredictability and machine specificity, the magnification and distortion of a cephalometric unit should be calibrated for the estimation of cephalometric measurement error.
Collapse
|
127
|
Ajoy A, Safvati B, Nazaryan R, Oon JT, Han B, Raghavan P, Nirodi R, Aguilar A, Liu K, Cai X, Lv X, Druga E, Ramanathan C, Reimer JA, Meriles CA, Suter D, Pines A. Hyperpolarized relaxometry based nuclear T 1 noise spectroscopy in diamond. Nat Commun 2019; 10:5160. [PMID: 31727898 PMCID: PMC6856091 DOI: 10.1038/s41467-019-13042-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Accepted: 09/27/2019] [Indexed: 12/03/2022] Open
Abstract
The origins of spin lifetimes in quantum systems is a matter of importance in several areas of quantum information. Spectrally mapping spin relaxation processes provides insight into their origin and motivates methods to mitigate them. In this paper, we map nuclear relaxation in a prototypical system of [Formula: see text] nuclei in diamond coupled to Nitrogen Vacancy (NV) centers over a wide field range (1 mT-7 T). Nuclear hyperpolarization through optically pumped NV electrons allows signal measurement savings exceeding million-fold over conventional methods. Through a systematic study with varying substitutional electron (P1 center) and [Formula: see text] concentrations, we identify the operational relaxation channels for the nuclei at different fields as well as the dominant role played by [Formula: see text] coupling to the interacting P1 electronic spin bath. These results motivate quantum control techniques for dissipation engineering to boost spin lifetimes in diamond, with applications including engineered quantum memories and hyperpolarized [Formula: see text] imaging.
Collapse
|
128
|
Lan L, Shao LM, Xiong F, Xie LY, Yu L, Han B, Wang QJ. [The ability of gap detection in patients with acoustic neuroma]. LIN CHUANG ER BI YAN HOU TOU JING WAI KE ZA ZHI = JOURNAL OF CLINICAL OTORHINOLARYNGOLOGY, HEAD, AND NECK SURGERY 2019; 33:1053-1056. [PMID: 31914293 DOI: 10.13201/j.issn.1001-1781.2019.11.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Indexed: 06/10/2023]
Abstract
Objective:We aimed to provide a basis for the clinical study of acoustic neuroma through investigating the ability of temporal gap detection in acoustic neuroma patients and comparing the abilities with those in people with normal and impaired hearing. Method:Twenty-two patients with confirmed acoustic neuroma, 30 normal hearing patients and 16 patients with sensorineural hearing loss were enrolled in this study, and the interval threshold for awareness of each group was tested. Result:The mean temporal gap detection test(TGDT) threshold of the normal hearing group was (3.56±0.82) ms; the sensorineural hearing loss group's was (3.91±1.46) ms; TGDT threshold of healthy side of acoustic neuroma patients was (4.01±1.86) ms; TGDT threshold of the impaired side of acoustic neuroma patients was (9.48±9.46)ms. After statistical analysis, we found that excepting for the test of phonetically balanced maximum (PBmax) and TGDT, other results in the sensorineural hearing loss group and normal hearing group is of no statistical difference. The difference between the affected side of the acoustic neuroma group and the other groups was statistically significant (P<0.05). There was no linear correlation between the value of TGDT threshold and PBmax (P> 0.05). TGDT value of normal people has no significant difference among people of different genders and ears of different individuals. Conclusion:The TGDT of the healthy ear of the patients with acoustic neuroma is not affected, and there is no significant change compared with normal people. The TGDT test has a good consistency with the PBmax results. The time interval response ability of the affected ear of the acoustic neuroma is significantly weaker than that of the normal person. The combined test of PBmax and TGDT will contribute to the diagnosis of retrocochlear disease.
Collapse
|
129
|
Nie W, Han B. Both low and high blood tumour mutational burden are favourable predictors with atezolizumab. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz438.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
130
|
Wang H, Zhu L, Zhang J, Han B, Wang Y. Predicting adverse outcomes of hypertensive disorders in pregnancy: validation of fullPIERS model in Chinese population. CLIN EXP OBSTET GYN 2019. [DOI: 10.12891/ceog4737.2019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
131
|
Han B, Li K, Chu T, Bi M, Zhang H, Yu Y, Shi J, Zhang X, Chen Z, Han C, Bai T. P1.01-03 Efficacy and Safety of Biosimilar QL1101 Compared with Avastin in Patients with Non-Squamous Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
132
|
Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Lou D, Yu H, Qin H, Li XL. Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz264.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
133
|
Li K, Cheng Y, Wang Q, Shi J, Han B, Wu L, Chen G, He J, Wang J, Qin H, Li X. P2.12-11 Quality of Life in ALTER1202 Trial of Anlotinib as Third-or Further Line Therapy for Advanced Small Cell Lung Cancer (SCLC): A Post-Hoc Analysis. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
134
|
Wang Q, Cheng Y, Li K, Shi J, Han B, Wu L, Chen G, He J, Wang J, Qin H, Li X. OA03.02 Effect of Anlotinib in Advanced Small Cell Lung Cancer Patients Previously Received Chemoradiotherapy: A Subgroup Analysis in ALTER 1202 Trial. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
135
|
Han B, Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, Qian J, Han Y. JCSE01.11 Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.269] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
136
|
Zhou Y, Zhong H, Han B. P2.01-85 Schwann Cells Are Overexpressed and Inversely Correlated with Survival of Non-Small Cell Lung Cancer Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
137
|
Lou Y, Xu J, Zhang Y, Lu J, Zhang X, Wang H, Zhang W, Han B. EP1.03-11 Mechanisms of Gefitinib Plus Pemetrexed on Human Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
138
|
Han B, Fang W, Zhang W, Wang S, Zhang L, Zhang B, Hu M, Zhao Y, Qian J. Comprehensive genomic profiling of thymic carcinoma in a sample Chinese population. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz266.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
139
|
Han B, Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, Qian J, Han Y. P1.04-02 Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.905] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
140
|
Lu J, Shi Q, Zhang L, Wu J, Zhang B, Wang S, Zhao X, Han B. P2.11-18 Circulating Serum KLK5 and L1CAM Levels Potentially Predict Clinical Outcome to Anlotinib Therapy in NSCLC Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
141
|
Han B, Chu T, Shi C, Zhong H, Zhang W, Zhang B, Zhong R, Zhang X. P2.01-21 Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
142
|
Han B, Chu T, Zhang X, Zhong H, Zhang B, Wang H, Gu A, Zhang W, Shi C, Zhong R. P1.01-95 Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.810] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
143
|
Cheng Y, Wang Q, Li K, Shi J, Han B, Wu L, Chen G, He J, Wang J, Qin H, Li X. P2.12-26 The Impact of Anlotinib for Relapsed SCLC Patients with Brain Metastases: A Subgroup Analysis of ALTER 1202. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1771] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
144
|
Chen D, Chu T, Chang Q, Zhang Y, Xiong L, Qiao R, Teng J, Han B, Zhong R. EP1.01-65 The Relationship Between Preliminary Efficacy and Prognosis After First-Line EGFR-TKI Treatment of Advanced NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
145
|
Hu F, Li C, Xu J, Guo J, Shen Y, Nie W, Zheng X, Wang L, Zhang H, Han B, Zhang X. MA01.10 Additional Local Consolidative Therapy Showed Survival Benefit Than EGFR-TKIs Alone in Bone Oligometastatic Lung Adenocarcinoma Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
146
|
Lu J, Zhong H, Wu J, Chu T, Zhang L, Li H, Wang Q, Li R, Zhao Y, Gu A, Shi C, Xiong L, Zhang X, Zhang W, Lou Y, Yan B, Dong Y, Zhang Y, Li B, Zhang L, Zhao X, Li K, Han B. MA25.09 Navigating Anlotinib Precision Therapy Through the Genetic Profiling of Circulating DNA in Non-Small Cell Lung Cancer Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
147
|
Castellano J, Navarro A, Molins L, Canals J, Marrades R, Viñolas N, Moises J, Casadevall M, Li Y, Han B, Martinez D, Martin J, Garisoain A, Muñoz C, Ramirez J, Monzo M. Pulmonary tumour-draining vein exosomal lincRNA-p21 levels impacts non-small cell lung cancer prognosis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz258.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
148
|
Mohanlal R, Sun Y, Kloecker G, Feinstein T, Shi Y, Han B, Bazhenova L, Du L, Huang L. P2.01-23 DUBLIN-3, a Phase (Ph) III Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone in Stage IIIb/IV NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1367] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
149
|
Zhang W, Xu J, Lou Y, Zhang Y, Han B. OA11.07 Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for EGFR Mutation NSCLC Patients: Update Data for NCT02148380. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
150
|
Zhang Y, Hu M, Han B. EP1.03-22 Prognostic Value of Serum Inflammation Biomarkers in Early Stage Lung Adenocarcinoma. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2103] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|